Table 3 –

Drugs affecting HDL Metabolism

Drugs	% HDL-C Elevation	Mechanism of Action	Stage of Development
Niacin	30-50	Multifactorial effects	Approved
Fibrates (Fenofibrate)	5-15	Multifactorial effects by acting as PPAR agonists	Approved
CETP- Inhibitors (Anacetrapib, Dalcetrapib)	25-135	Inhibit transfer of cholesteryl esters away from HDL	Phase III (completed)
BET Inhibitor (Apabetalone)	5-10	Epigenetic modification altering apoA-I transcription	Phase III (completed)
HDL Infusion Therapy (CSL-112)	50-200	Direct infusion of exogenous HDL	Ongoing Phase III (AEGIS-II: NCT03473223)
Recombinant LCAT (MEDI6012)	50-100	Increase esterification of cholesterol on HDL	Ongoing Phase II ((REAL-TIMI 63B: NCT03578809))

HDL=high density lipoprotein; PPAR=peroxisome proliferator-activated receptor; CETP=cholesteryl ester transfer protein; BET=bromodomain and extraterminal; apoA-I=apolipoprotein A-I; AEGIS=ApoA-I Event reducing in Ischemic Syndromes; LCAT=lecithin-cholesterol acyltransferase;